Comparative Pharmacology
Head-to-head clinical analysis: PIPERACILLIN AND TAZOBACTAM versus POLYMOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PIPERACILLIN AND TAZOBACTAM versus POLYMOX.
PIPERACILLIN AND TAZOBACTAM vs POLYMOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Piperacillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), while tazobactam is a beta-lactamase inhibitor that protects piperacillin from degradation by beta-lactamases.
Amoxicillin is a bactericidal antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs) and inhibiting transpeptidase activity, leading to cell lysis.
3.375 g (piperacillin 3 g + tazobactam 0.375 g) IV every 6 hours, or 4.5 g (piperacillin 4 g + tazobactam 0.5 g) IV every 8 hours for nosocomial pneumonia.
250-500 mg orally every 8 hours or 500-875 mg orally every 12 hours; maximum 4 g/day.
None Documented
None Documented
Piperacillin ~0.7–1.2 h, tazobactam ~0.7–1.5 h; prolonged in renal impairment (piperacillin up to 3.3 h, tazobactam up to 5.6 h in severe impairment).
Terminal elimination half-life = 1-1.5 hours in adults; prolonged in renal impairment (up to 12-20 hours in anuria)
Primarily renal: piperacillin ~68% unchanged, tazobactam ~80% unchanged; biliary excretion <10%; fecal <1%.
Renal (70-80% unchanged via tubular secretion and glomerular filtration); biliary/fecal (small amount, <5%)
Category C
Category C
Penicillin Antibiotic / Beta-Lactamase Inhibitor Combination
Penicillin Antibiotic